SIMVASTATIN
Platinum-sensitive Ovarian Cancer
Marc GoodmanSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Platinum-sensitive Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ivonescimab Akeso | Phase 2 | B |
ose2101 ARCAGY/ GINECO GROUP | Phase 2 | CCC |
rp12146 Rhizen Pharmaceuticals SA | Phase 1 | CC |
Same molecule, other indications
SIMVASTATIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →